Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug;62(8):10443-10467.
doi: 10.1007/s12035-025-04910-9. Epub 2025 Apr 10.

Evaluation of the Sporadic Anti-Alzheimer's Activity of Purpurin Using In Silico, In Vitro, and In Vivo Approaches

Affiliations

Evaluation of the Sporadic Anti-Alzheimer's Activity of Purpurin Using In Silico, In Vitro, and In Vivo Approaches

Kajol Rustage et al. Mol Neurobiol. 2025 Aug.

Abstract

Purpurin, a naturally occurring compound found in certain plants, has demonstrated promising neuroprotective effects in the context of Alzheimer's disease (AD). This study investigated the efficacy of purpurin in mitigating neurodegenerative changes induced by streptozotocin (3 mg/kg ICV) and amyloid beta (20 μM) in murine models. Neuroprotective effects were assessed through in vitro and in vivo experiments complemented by in silico simulation studies. SH-SY5Y cell viability, behavioral, biochemical, and histopathological studies were also conducted. The results revealed that purpurin interacts with acetylcholinesterase (AChE) and amyloid-beta (Aβ), exhibiting glide scores of - 10.72 and - 3.05 kcal/mol, respectively. Purpurin (8 μM) significantly alleviated Aβ-induced cellular damage by decreasing malondialdehyde production and enhancing superoxide dismutase and Thio barbituric acid reactive substances levels in a dose-dependent manner. Intraperitoneal administration of purpurin at 50 mg/kg significantly improved both long-term and short-term memory and enhanced social interactions. These benefits were linked to the reductions in AChE activity and oxidative and inflammatory marker levels triggered by streptozotocin. Neuroprotective effects were also supported by restoring neuronal DNA content in the hippocampus, cerebellum and prefrontal cortex. Histological findings further corroborated the reduction in neurodegenerative marker levels. In silico simulations supported these findings by indicating that purpurin primarily binds to the Trp 286 and Tyr 341 residues of AChE, inhibiting its catalytic activity at the peripheral anionic site. In conclusion, the neuroprotective activity of purpurin in AD models is attributed to its inhibitory effects on AChE, coupled with reductions in inflammation and oxidative stress and the restoration of neuronal DNA integrity in critical brain regions.

Keywords: Alzheimer’s disease; Amyloid beta; Memory; Purpurin; Social behavior; Streptozotocin.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics Approval: All the animal experiments (Ref. no. BV/3533/2017–18) were preapproved by the Institutional Animal Ethical Committee of Banasthali Vidyapith, and the animal experiments were performed according to the CPCSEA guidelines. Consent to Participate: Not applicable. Consent for Publication: Not applicable. Competing Interests: The authors declare no competing interests.

Similar articles

Cited by

References

    1. Alzheimer’s Association Annual Report. Vol 13. Chicago; 2015. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&a... . Accessed on 28 July 2024
    1. Alzheimer association; 10 Early Signs and Symptoms of Alzheimer’s & Dementia. https://www.alz.org/alzheimers-dementia/10_signs Accessed on 24 July 2024
    1. Santana I, Farinha F, Freitas S et al (2015) The epidemiology of dementia and Alzheimer disease in Portugal: estimations of prevalence and treatment-costs. Acta Med Port 28:182–188. https://doi.org/10.20344/amp.6025 - DOI - PubMed
    1. Anand R, Gill KD, Mahdi AA (2014) Therapeutics of Alzheimer’s disease: past, present and future. Neuropharmacology 76:27–50. https://doi.org/10.1016/j.neuropharm.2013.07.004 - DOI - PubMed
    1. Vaz M, Silva V, Monteiro C et al (2022) Role of aducanumab in the treatment of alzheimer’s disease: challenges and opportunities. CIA 17:797–810. https://doi.org/10.2147/CIA.S325026 - DOI

LinkOut - more resources